ArticleAnnals of hematology2026
Association between metabolic overweight/obesity phenotypes and readmission risk in patients with Immune Thrombocytopenia (ITP): a national retrospective study.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Immune thrombocytopenia (ITP) is one of the most common autoimmune hemorrhagic disorders and is characterized by frequent relapses that require repeated hospitalization. Although overweight/obesity and metabolic disorders have been linked to ITP, their association with readmission risk remains unclear. A cohort of 3,811 patients with a discharge diagnosis of ITP was identified from the National Readmission Database (NRD) for this retrospective analysis. Patients were classified into four phenotypes according to overweight/obesity status and metabolic status: metabolically healthy non-obese (MHNO), metabolically unhealthy non-obese (MUNO), metabolically healthy obese (MHO), and metabolically unhealthy obese (MUO). Readmissions were assessed at 30, 60, 90, 120, 150, and 180 days. Multivariable Cox proportional hazards models were used to evaluate the association between metabolic overweight/obesity phenotypes and readmission risk in this cohort. At 120, 150, and 180 days, patients with metabolically unhealthy phenotypes had a significantly higher risk of readmission than those with the MHNO phenotype. In contrast, the MHO phenotype was not associated with increased readmission risk. Subsequent stratified analyses showed a gradual increase in readmission risk with a higher number of concurrent metabolic risk factors. Among patients with ITP, metabolic disorders, rather than overweight/obesity, were associated with an increased risk of readmission after multivariable adjustment. Readmission risk also increased with the number of concurrent metabolic risk factors. Notably, the association between metabolic comorbidities and ITP-related readmission showed a distinct time-dependent pattern. Because this study did not include a non-ITP control group, whether this association is specific to ITP or reflects a broader effect of metabolic comorbidities on readmission remains uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.